The best pain killers are safe, effective and affordable, according to the makers of an antibiotic commonly used to treat bacterial infections.
Dr. David K. Weill, a physician in New York City, said that he has tested more than 2,000 medications for stomach pain and found that only one, an opioid called Zohydro, was effective for the disease.
The other four drugs, including hydrocodone, were more effective, Weill said.
Weill’s findings have spurred concern among doctors, advocates and patients that the medication is being overprescribed.
Weil has also been criticized for his work in treating bacterial infections, and in 2015, he published a controversial book, “What Doctors Don’t Want You to Know About Drugs.”
The antibiotic is commonly used for urinary tract infections, but in most cases, it has no effect on the growth of bacteria.
Weish’s study, however, is the first to show that the drug has the ability to prevent bacterial infections that can lead to life-threatening infections like tuberculosis and stomach cancer.
Weish and colleagues used an electronic health record (EHR) system to compare the prescribing habits of 1,000 patients who had chronic ulcerative colitis and a primary bacterial infection, including gastric ulcer and gastric cancer.
Weished and colleagues compared the prescriptions of Zohydra, an antibiotic, with hydrocoda and the other three antibiotics.
The researchers found that the Zohydros were more likely to be prescribed for chronic ulcers than for gastric cancers.
Weills team also found that Zohydralo was more effective than hydrocods for chronic stomach ulcers.
The team is now reviewing other data that Weish has collected from other patients and physicians in the United States.
The drug, Weish said, may be better suited for other illnesses that require fewer antibiotics.
“This could be a great drug for treating other bacterial infections,” Weish told The Associated Press.
“Weill is a good friend of mine, and I believe he will be able to help the American people with this new drug.”
Kirsten O’Connor, chief medical officer of Doctors Without Borders, told the AP that Weill’s study “represents an important first step in understanding how this drug works in treating other forms of ulcer disease.”
Weill also said he hopes to study the drug’s effectiveness against other bacterial diseases.
“If this drug can be used to help alleviate other gastrointestinal infections, it will be an important tool in the fight against antibiotic-resistant bacteria,” he said.
The drug is a blend of hydrocodyl and hydrococodone.
It has been approved for treating bacterial infection and gastrointestinal disease.
In the United Kingdom, a study published in March found that people who took the drug experienced an improvement in symptoms of the common stomach ulcer.
“The drugs were given to patients in the most intensive care units, where patients were given an intravenous dose and had to wait for two hours before receiving an injection,” Dr. David Jones, the study’s senior author, said.
“It was a very slow and controlled study, so it is very difficult to say how effective the drugs were.”